Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

08:47 EST 26th November 2014 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

[News] FOLFOXIRI and bevacizumab in metastatic colorectal cancer

First-line bevacizumab with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) improves survival outcomes in patients with metastatic colorectal cancer, according to a new trial.

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, leucovorin, and irinotecan (FOLFIRI) pl...

[Comment] Cetuximab or bevacizumab in metastatic colorectal cancer?

In The Lancet Oncology, Volker Heinemann and colleagues report the results of FIRE-3, a randomised phase 3 trial comparing cetuximab with bevacizumab, in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI), for the first-line treatm...

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal c...

ESMO GI: Cetuximab or bevacizumab with combi chemo equivalent in KRAS wile-type metastic colorectal cancer

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “The...

Cetuximab delivers better overall survival than bevacizumab in metastatic colorectal cancer

by ecancer reporter Janet Fricker Patients with KRAS exon 2 wild type metastatic colorectal cancer achieve longer overall survival with FOLFIRI plus cetuximab than FOLFIRI plus bevacizumab, concluded the FIRE-3 trial published in Lancet Oncology. W...

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Results from a large federally funded phase III study demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cance...

CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen

Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

[News] UK Cancer Drugs Fund to reassess 42 agents

National Health Service (NHS) England has announced a re-evaluation of 42 drugs funded by the controversial Cancer Drugs Fund (CDF) based on cost-effectiveness. The drugs include bevacizumab for breast, ovarian, and colorectal cancer, cetuximab for c...

[Articles] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Although the proportion of patients who achieved an objective response did not significantly differ between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab groups, the association with longer overall survival suggests that FOLFIRI plus cetuxi...

Bevacizumab, Cetuximab Have Similar Survival Benefits in CRC

Adding either bevacizumab or cetuximab to chemotherapy yielded equal benefits in metastatic colorectal cancer (CRC). Medscape Medical News

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastroin...

From ASCO—colorectal cancer: Cetuximab or bevacizumab with chemo: take your pick

ASCO: Chemo Plus Avastin or Erbitux Boosts Colorectal Ca Survival

CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical ...

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

At a press conference at ASCO 2014, Dr Venook presents the results from a large federally funded phase III study which demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – ar...

Biosimilars of bevacizumab

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in t...

[Articles] Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled tr

Adjuvant FOLFOX improves disease-free survival compared with fluorouracil plus leucovorin in patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision, and warrants further investigation.

Genetic testing of tumor is recommended for colorectal cancer patients

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumor...

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX o...

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer

[News] Adenoma removal and colorectal cancer mortality

Patients who have low-risk adenomas removed have a reduced risk of dying from colorectal cancer compared with the general population, according to a new study. The researchers linked Norway's National Cancer Registry with its Cause of Death Registry...

Support for fecal testing in familial colorectal cancer screening

Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, the official journal of ...

[Articles] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Despite prematurely terminated accrual and the lack of information about post-progression treatment, both progression-free survival and overall survival were significantly improved with bevacizumab and capecitabine compared with bevacizumab alone as ...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks